Government support for biotech touted as driver for ID Biomedical’s successful sale of influenza vaccine into US market
Guest ContributorDecember 7, 2004
Vancouver’s ID Biomedical Corp (IDB) has scored a spectacular home run with a long-term agreement to sell its Fluviral influenza vaccine — produced and commercialized in Canada — into the US market.
Other stories mentioning these organizations, people and topics
Other News
Events For Leaders in
Science, Tech, Innovation, and Policy
Discuss and learn from those in the know at our virtual and in-person events.
See Upcoming Events
You have 0 free articles remaining.
Don't miss out - start your free trial today.
Start your FREE trial Already a member? Log in
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.